Application of glycerinum-3-phosphoric acid and adjuvant containing glycerinum-3-phosphoric acid and vaccine agent

A technology of glycerol and phosphoric acid, which is applied in the field of immunology, can solve the problems of high price and insignificant immune response effect, and achieve the effects of low cost, improved immune response level and stable performance

Active Publication Date: 2018-07-27
INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] In order to solve the problems of the existing vaccine adjuvants such as high price and insignificant effect of promoting immune response, the present invention provides the application of glycerol-3-phosphate in the preparation of vaccine adjuvants, and provides an economical, effective, safe and stable Adjuvant and vaccine agent containing glycerol-3-phosphate and preparation method thereof

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of glycerinum-3-phosphoric acid and adjuvant containing glycerinum-3-phosphoric acid and vaccine agent
  • Application of glycerinum-3-phosphoric acid and adjuvant containing glycerinum-3-phosphoric acid and vaccine agent
  • Application of glycerinum-3-phosphoric acid and adjuvant containing glycerinum-3-phosphoric acid and vaccine agent

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] The Hepatitis A vaccine containing glycerol-3-phosphate adjuvant provided in this example is: after dissolving 2 μl glycerol-3-phosphate with 54 μl normal saline, a solution with a content of 1 mg glycerol-3-phosphate adjuvant is obtained, and the adjuvant is routinely added every A single portion of HAV antigen (that is, a single injection dose used in animal experiments), and finally add physiological saline (PH=7.4) to 300 μL, and mix evenly to obtain a hepatitis A vaccine containing glycerol-3-phosphate.

[0021] Glycerol-3-phosphate, also known as glycerol phosphate, molecular formula: C 3 h 9 o 6 P, molecular weight: 172.07, purchased from J&K, CASNO.57-03-4; live attenuated hepatitis A vaccine, antigen titer 18EU / ml, purchased from Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College.

[0022] Gained immunity test and the effect of the hepatitis A vaccine containing glycerol-3-phosphate adjuvant are as follows:

[002...

Embodiment 2

[0038] The Hepatitis A vaccine containing glycerol-3-phosphate adjuvant provided in this example is: after dissolving 4 μl glycerol-3-phosphate with 54 μl normal saline, a solution with a content of 2 mg glycerol-3-phosphate adjuvant is obtained, and the adjuvant is routinely added every A single portion of HAV antigen (that is, a single injection dose used in animal experiments), and finally add physiological saline (PH=7.4) to 300 μL, and mix evenly to obtain a hepatitis A vaccine containing glycerol-3-phosphate. Wherein the aluminum hydroxide adjuvant and HAV antigen are obtained in the same manner as in Example 1.

[0039] The immune test of the hepatitis A vaccine containing glycerol-3-phosphate adjuvant obtained in this example is the same as in Example 1, and the results are shown in Table 2. Table 2 shows the serum anti-HAV IgG antibody levels of mice in each experimental group within 20 weeks after using the adjuvant provided in Example 2.

[0040] Table 2

[0041] ...

Embodiment 3

[0045]The Hepatitis A vaccine containing glycerol-3-phosphate adjuvant provided in this example is: after dissolving 8 μl glycerol-3-phosphate with 54 μl normal saline, a solution with a content of 4 mg glycerol-3-phosphate adjuvant is obtained. A single portion of HAV antigen (that is, a single injection dose used in animal experiments), and finally add physiological saline (PH=7.4) to 300 μL, and mix evenly to obtain a hepatitis A vaccine containing glycerol-3-phosphate. Wherein the aluminum hydroxide adjuvant and HAV antigen are obtained in the same manner as in Example 1.

[0046] The immune test of the hepatitis A vaccine containing glycerol-3-phosphate adjuvant obtained in this example is the same as that in Example 1, and the results are shown in Table 3. Table 3 shows the serum anti-HAV IgG antibody levels of mice in each experimental group within 20 weeks after using the adjuvant provided in Example 3.

[0047] table 3

[0048]

[0049] Through data analysis, it ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of glycerinum-3-phosphoric acid and an adjuvant containing the glycerinum-3-phosphoric acid and a vaccine agent. The use of the glycerinum-3-phosphoric acid as theadjuvant in the vaccine: each part of a vaccine solution contains 1 to 8 mg of glycerinum-3-phosphoric acid. The adjuvant containing the glycerinum-3-phosphoric acid is prepared from 54 micro liters of normal saline and 1 to 8 mg of glycerinum-3-phosphoric acid. The adjuvant is easy in obtaining the raw material, the vaccine is simple in preparation process, low in cost, stable in performance, small in toxicity and side effects, capable of rapidly stimulating the immune response reaction, small and reliable in use in the range of the immune dosage, capable of effectively inducing the body fluid immune response of the antigen specificity, and capable of significantly improving the body fluid immune reaction of the antigen specificity, and the effect is better than that of the adjuvant-freegroup and equivalent to that of the aluminum adjuvant group.

Description

technical field [0001] The invention relates to the application of glycerol-3-phosphate, an adjuvant containing glycerol-3-phosphate and a vaccine agent, belonging to the field of immunology. Background technique [0002] Vaccines are the most effective means for humans to prevent and control infectious diseases. Vaccination is estimated to prevent more than 2.5 million deaths per year. Vaccines put into use on the market are generally composed of antigens and adjuvants, and immune adjuvants play an important role in the function of vaccines. important role. Adjuvants can quickly activate the immune system, which is even more important for immunocompromised children and the elderly. The development of technologies such as bioinformatics, structural biology and reverse genetics has provided new directions and ideas for the development of new vaccines in the future. The rapid development of new vaccines has drawn attention to the safety of adjuvants and the enhanced effect of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/39A61K39/125A61P31/14
CPCA61K39/12A61K39/39A61K2039/5254A61K2039/55511A61P31/14C12N2770/32334
Inventor 胡凝珠金晓胡云章孙静乌美妮李建芳李彦涵施建东
Owner INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap